Jaguar Health, Inc. (JAGX) News
Filter JAGX News Items
JAGX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
JAGX News Highlights
- JAGX's 30 day story count now stands at 5.
- Over the past 18 days, the trend for JAGX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest JAGX News From Around the Web
Below are the latest news stories about JAGUAR HEALTH INC that investors may wish to consider to help them evaluate JAGX as an investment opportunity.
11 Popular Penny Stocks on RobinhoodIn this article, we discuss the 11 popular penny stocks on Robinhood. If you want to skip our detailed analysis of these stocks, go directly to 5 Popular Penny Stocks on Robinhood. Even though the United States economy has battled recession fears in the past few months, there are many reasons to be optimistic about […] |
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 61%Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders won't be pleased to see that the share price has had a very rough... |
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage IIStage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on trackCancer patients at patient advocacy events voice strong support for company's focus on patient quality of life and ... |
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family CompanyTo register for the webinar, click hereSAN FRANCISCO, CA / ACCESSWIRE / December 7, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that a Multinational Association of Supportive Care in Cancer ... |
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) WebsiteSAN FRANCISCO, CA / ACCESSWIRE / December 6, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the abstract for "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis ... |
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in DogsCanalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDACrofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is the ... |
Jaguar Health to Present December 5 at the MedInvest Oncology Investor ConferenceTop line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcomingSAN FRANCISCO, CA / ACCESSWIRE / November 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ... |
Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy ForthcomingSAN FRANCISCO, CA / ACCESSWIRE / November 21, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the company has not yet been provided with results from the company's GCP (Good Clinical Practice) ... |
Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2023 Earnings Call TranscriptJaguar Health, Inc. (NASDAQ:JAGX) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning. Before I turn the call over to management, I’d like to remind you that management may make forward-looking statements relating to such matters as Contenued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive […] |
FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTSFilament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its third quarter financial results and operational highlights for the period ended September 30, 2023. |